Back to top

biotechs: Archive

Zacks Equity Research

FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List

The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.

NVOPositive Net Change LLYPositive Net Change HIMSNegative Net Change

Ekta Bagri

ADMA Biologics Stock Skyrockets 262.1% YTD: How to Play the Stock?

ADMA stock rallies 262.1% in the year-to-date period on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.

GRFSNegative Net Change ADMAPositive Net Change TAKPositive Net Change

Zacks Equity Research

GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.

REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change

Zacks Equity Research

GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals

The phase III ANCHOR-1 and ANCHOR-2 studies evaluating GSK's depemokimab in adults with chronic rhinosinusitis with nasal polyps meet co-primary endpoints.

REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change GSKPositive Net Change

Zacks Equity Research

VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises

Vanda's board of directors unanimously rejects the second takeover proposal from Cycle Group Holdings. Shares rise on the news.

ALNYPositive Net Change JNJPositive Net Change VNDANegative Net Change ANIPNegative Net Change

Zacks Equity Research

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

LBPH stock soars 52% on announcing that it is set to be acquired by Lundbeck for a total consideration of $2.6 billion to bolster the latter's neuro pipeline.

ALNYPositive Net Change ANIPNegative Net Change XENEPositive Net Change

Zacks Equity Research

RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug

Repare stock gains 8% as the company initiates dosing patients in its phase I study of the RP-3467 combo regimen for advanced solid tumor indications.

AZNPositive Net Change ALNYPositive Net Change ANIPNegative Net Change RPTXPositive Net Change

Zacks Equity Research

Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.

ALNYPositive Net Change BMYPositive Net Change MRKPositive Net Change EXELNegative Net Change

Zacks Equity Research

Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi

Following the FDA approval, PFE's Hympavzi becomes the first hemophilia medicine approved in the United States to be administered via a pre-filled, auto-injector pen.

PFEPositive Net Change BMRNNegative Net Change NVOPositive Net Change QUREPositive Net Change

Zacks Equity Research

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe

ITCI is seeing strong Caplyta sales, driven by a high prescription rate. However, its heavy reliance on the drug's sales for growth is concerning.

XENEPositive Net Change AXSMPositive Net Change

Zacks Equity Research

Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted population. A potential approval should boost GILD???s HIV portfolio.

GSKPositive Net Change PFEPositive Net Change GILDNegative Net Change

Zacks Equity Research

Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition?

AXSM's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. Stiff competition in the target market remains a concern.

JAZZPositive Net Change ACADPositive Net Change AXSMPositive Net Change

Zacks Equity Research

QIAGEN's TB Testing Business Gets New Exposure at Global Summit

QGEN distributes over 125 million QuantiFERON-TB tests across more than 130 countries worldwide, significantly contributing to national TB control strategies.

ABTPositive Net Change HOLXNegative Net Change QGENPositive Net Change RVTYPositive Net Change

Nalak Das

5 Stocks With Recent Price Strength Amid October Volatility

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.

CORTNegative Net Change ADMAPositive Net Change QFINNegative Net Change VRTPositive Net Change ATATPositive Net Change

Zacks Equity Research

GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy

New data from GSK's phase III study evaluating a single dose of RSV vaccine Arexvy indicates protection over three RSV seasons in adults aged 60 years and above.

GSKPositive Net Change PFEPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks

KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.

REGNPositive Net Change BAYRYPositive Net Change KODPositive Net Change

Zacks Equity Research

Kymera's IND Application for STAT6 Degrader Gets FDA Clearance

KYMR will initiate dosing in a phase I study on KT-621, an investigational first-in-class once daily, oral STAT6 degrader, following IND clearance by the FDA.

REGNPositive Net Change SNYPositive Net Change KYMRPositive Net Change

Zacks Equity Research

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening

Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.

ILMNPositive Net Change MYGNNegative Net Change EXASPositive Net Change VCYTPositive Net Change

Zacks Equity Research

BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?

While the recent spate of positive regulatory updates boosts Bristol Myers, we will advise a wait-and-watch strategy.

BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change

Zacks Equity Research

PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program

PTC Therapeutics announces positive results from long-term treatment studies on vatiquinone for the treatment of Friedreich ataxia.

ALNYPositive Net Change PTCTPositive Net Change ANIPNegative Net Change

Ahan Chakraborty

Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?

Despite the recent pipeline setback, investors are encouraged to buy the FULC stock based on the potential of its promising SCD candidate, pociredir.

VRTXPositive Net Change CRSPPositive Net Change FULCPositive Net Change

Zacks Equity Research

SLNO Stock Rises on Upbeat Regulatory Update on PWS Drug NDA

Soleno stock gains as the FDA says no advisory committee meeting is required for the DCCR NDA at present to treat hyperphagia associated with PWS.

ALNYPositive Net Change ANIPNegative Net Change ACADPositive Net Change SLNONegative Net Change

Zacks Equity Research

Regeneron Gains 13.5% Year to date: How to Play the Stock?

REGN maintains momentum as Eylea HD gains traction and Dupixent maintains momentum, even as lead drug Eylea faces challenges.

REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYPositive Net Change

Zacks Equity Research

NTLA Begins Phase III Study on Hereditary Angioedema Candidate

Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).

REGNPositive Net Change ALNYPositive Net Change ANIPNegative Net Change NTLAPositive Net Change

Debanjana Dey

Zacks Initiates Coverage of Earth Science Tech With Neutral Recommendation

Discover why Zacks rates Earth Science Tech as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore ETST's promising growth prospects and financial health amid market challenges.

ETSTPositive Net Change